www.fdanews.com/articles/138938-sec-charges-bio-company-executives-for-misleading-investors-on-drug-8217-s-status
SEC Charges Bio Company, Executives for Misleading Investors on Drug’s Status
August 3, 2011
The SEC is charging biopharmaceutical company Immunosyn, three shareholder companies and four senior executives for “fraudulently misleading” investors on the regulatory status of its investigational drug.
Drug Industry Daily
Drug Industry Daily